Mutations with prognostic value in uveal melanoma: analytical study of variants detected by targeted next-generation sequencing.
Summary
This retrospective study utilized targeted next-generation sequencing to identify genetic variants with prognostic value in uveal melanoma. Mutations in BAP1, CHEK2, and DICER1 were independently associated with a poorer prognosis and increased metastatic risk. Furthermore, BAP1 and LRP1B mutations were linked to epithelioid/mixed histology, while SF3B1 mutation was associated with spindle cell morphology. These findings suggest that mutational profiling could improve risk stratification and patient follow-up.
Analysis
🔴 CLINIQUE: This retrospective study identifies significant prognostic biomarkers for uveal melanoma. BAP1, CHEK2, and DICER1 mutations are associated with increased metastatic risk, in addition to tumor size (HR = 3.07) and mitotic index (HR = 1.31). Integrating targeted NGS mutational profiling into clinical practice could refine risk stratification and guide patient follow-up, potentially within 3-5 years. 🟢 BIOMOL: The discovery of mutations in BAP1, CHEK2, and DICER1 as poor prognostic markers, and SF3B1 for a distinct histological subgroup, represents a significant advance. The technology used is targeted next-generation sequencing, applied to tumor samples from choroidal melanoma treated by enucleation, allowing for precise detection of pathogenic variants across 28 genes. 🔵 BIOINFO: The study utilized Cox regression and multivariable logistic regression analyses to assess genetic associations. Internal model validation through bootstrap resampling demonstrated good predictive performance with a corrected Harrell's C-index score of 0.801. This strengthens the robustness of the identified associations and suggests the potential for integrating these models into clinical workflows for decision support.